A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? by Pea, Federico et al.
A 10-Year Experience of Therapeutic Drug Monitoring (TDM)
of Linezolid in a Hospital-wide Population of Patients Receiving
Conventional Dosing: Is there Enough Evidence for Suggesting
TDM in the Majority of Patients?
Federico Pea1,2, Pier Giorgio Cojutti1,2 and Massimo Baraldo1,2
1Institute of Clinical Pharmacology, Santa Maria della Misericordia, University Hospital of Udine, ASUIUD, Udine, Italy and 2Department of
Medicine, University of Udine, Udine, Italy
(Received 15 March 2017; Accepted 6 April 2017)
Abstract: A retrospective study was conducted to assess our 10-year experience of therapeutic drug monitoring (TDM) of line-
zolid in a large patient population to establish whether conventional dosing may result in adequate drug exposure in the majority
of patients. Patients included in this study underwent TDM of linezolid trough concentration (Cmin) during treatment with con-
ventional doses of 600 mg every 12 hr in the period between January 2007 and June 2016. The desired range of Cmin was set
between 2 and 7 mg/L (underexposure, Cmin < 2 mg/L; overexposure, Cmin > 7 mg/L). Multivariate logistic regression analysis
investigated variables potentially correlated with linezolid Cmin. One thousand and forty-nine patients had 2484 linezolid Cmin
assessed during treatment with conventional doses. Median (IQR) linezolid Cmin was 5.08 mg/L (2.78–8.52 mg/L). Linezolid
Cmin was within the desired range in 50.8% of cases (1262/2484). Overexposure (n = 821; 33%) occurred much more frequently
than underexposure (n = 401; 16.2%) and was severe (>20 mg/L) in 3.9% of cases (98/2484). Linezolid overexposure was sig-
nificantly associated with CrCLC-G estimates ≤40 mL/min. (OR 1.463; 95% CI 1.124–1.904, p = 0.005). Linezolid underexpo-
sure was significantly associated with CrCLC-G estimates >100 mL/min. (OR 3.046; 95% CI 2.234–4.152, p < 0.001). Linezolid
Cmin was not correlated linearly with CrCLC-G (R
2 = 0.061). Variability in renal function explained only partially the very wide
interindividual linezolid Cmin variability. Our study suggests that TDM could represent a valuable approach in optimizing line-
zolid exposure in the majority of patients.
In the era of precision medicine and of emergence of antimi-
crobial resistance, therapeutic drug monitoring (TDM) is pro-
gressively gaining a major role in optimizing treatment with
several antimicrobials [1,2]. Linezolid is an oxazolidinone
antibiotic with time-dependent activity, which is licensed at
the conventional dose of 600 mg every 12 hr for the treatment
of pneumonia and of skin and soft tissue infections due to
Gram positives [3]. Nowadays, the use of linezolid in daily
clinical practice has been widened to include the treatment for
other difficult infections, such as prosthetic and bone and joint
infections, and multi-drug resistant (MDR) tuberculosis [4–6].
This has posed some safety concerns, considering that the
duration of treatment is restricted to 28 days maximum due to
the risk of drug-related adverse events [7,8].
Over the last couple of years, the interest on TDM of line-
zolid has consistently increased. Our group was among the
first in observing that linezolid plasma exposure may vary
greatly during treatment with conventional doses [9]. Subse-
quently, we and other authors suggested that maintenance of
linezolid trough concentrations (Cmin) within a pre-defined
range may be helpful in preventing drug-related adverse
events, while preserving therapeutic effectiveness [10]. We
supposed that the interindividual variability of linezolid Cmin
may be related mainly to drug–drug interactions [9,11–14].
Other authors suggested that linezolid Cmin may be influenced
also by the degree of renal function [15], by the severity of
critical illness [16,17] or even by some other factors [18,19].
The aim of this study was to assess retrospectively our 10-
year experience of TDM of linezolid Cmin in a large patient
population while receiving conventional doses to establish
whether the standard dosing regimen may result in adequate
drug exposure or not in the majority of patients.
Methods
Study design. This retrospective observational study was carried out
between January 2007 and June 2016 at the Santa Maria della
Misericordia University Hospital, Udine, Italy. Patients included in this
study were those admitted to intensive care units (ICUs) or to medical or
surgical wards who were treated intravenously or orally with linezolid at
the conventional dose of 600 mg every 12 hr because of documented or
suspected MDR Gram-positive bacterial infections and who underwent
TDM. The aim of this study was to assess the dimension of the
interindividual variability of plasma linezolid Cmin observed during the
conventional dosing regimen. Consistently, we included in this analysis
only the TDM carried out before the eventual application of TDM-
guided dosage adjustments of linezolid, which usually are applied
promptly by clinicians at our University Hospital [20].
The Regional Ethics Committee approved the study, and informed
written consent was waived according to the retrospective and obser-
vational nature of the study.
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Linezolid TDM is performed thrice weekly at our institution (on
Monday, Wednesday and Friday), and the clinical pharmacological
advice for dosage adjustment is provided via intranet within the same
day to clinician. Dosage adjustment is recommended whenever line-
zolid Cmin is outside of the desirable range of 2–7 mg/L, which was
identified in a previous study [10]. Distributions of linezolid Cmin were
defined as follows: desired therapeutic range, when Cmins were
between 2 and 7 mg/L; underexposure, when Cmins were <2 mg/L;
overexposure, when Cmins were >7 mg/L. Linezolid overexposure was
divided into three classes according to severity: mild, when Cmins ran-
ged between 7.01 and 10 mg/L; moderate, when Cmins ranged
between 10.01 and 20 mg/L; and severe, when Cmins were >20 mg/L.
The following data were retrieved from the patient data sheets
stored at our institution: age, gender, total body-weight (TBW), height,
body mass index (BMI), serum creatinine and linezolid Cmin. Data on
patient comedications were not included in the analysis because they
were not collected systematically during TDM assessments in all of
the cases. Creatinine clearance (CrCL) was estimated by means of the
Cockcroft and Gault formula (CrCLC-G).
Blood samples for TDM were collected immediately before dosing
after at least 48 hr from starting linezolid therapy. Linezolid plasma
concentrations were analysed by means of a validated high-
performance liquid chromatography (HPLC) method with UV detec-
tion, as previously described [9,10]. Precision and accuracy were
assessed by performing replicate analysis of quality control samples
against calibration standards. Intra- and interassay coefficients of varia-
tion were always <10%. The lower limit of detection was 0.2 mg/L.
Statistical analysis. The Kolmogorov–Smirnov test was used to assess
normal or non-normal distribution of data. Accordingly, means  S.D.
or medians with 25th and 75th interquartile range (IQR) were used for
descriptive statistics. One-way ANOVA on ranks was used for
comparing data among different groups. Univariate logistic regression
analysis was used to investigate variables potentially correlated with
linezolid Cmin. All the independent variables associated with p ≤ 0.05
at the univariate analysis were included in the multivariate logistic
regression model. p ≤ 0.05 was considered for statistical significance.
Statistical analysis and plotting were performed with R version 3.3.1
(R Foundation for Statistical Computing, Vienna, Austria).
Results
One thousand and forty-nine patients who had 2484 Cmin
assessed during treatment with conventional doses of linezolid
were included in the study (table 1). Median age was
65 years. The majority of patients were male (717/1049;
68.4%) and were admitted mainly in medical wards (470/
1049; 44.8%). Median serum creatinine and estimated CrCLC-
G were 0.9 mg/dL and 75.7 mL/min, respectively. The oral
and the intravenous route for the administration of linezolid
were almost equally distributed among the study population
(50.2 and 49.8%, respectively). Overall, median linezolid Cmin
was of 5.08 mg/L during conventional dosing. Linezolid Cmin
fell within the desired range in around half of cases (1262/
2484; 50.8%). Overexposure (n = 821; 33%) occurred much
more frequently than underexposure (n = 401; 33% versus
16.2%) and was severe in 3.9% of cases (98/2484). Occur-
rence of linezolid under- or overexposure was unrelated to the
duration of treatment and to the type of ward of admission.
Histogram and Kernel density plot (fig. 1) showed that line-
zolid Cmin had a log-normal distribution in the study popula-
tion. Beeswarm plots of the individual linezolid Cmin (fig. 2)
showed that the distributions of linezolid Cmin were similar
among patients admitted to medical wards, surgical wards and
the ICUs (median Cmin 4.91 mg/L versus 5.16 mg/L versus
5.8 mg/L; p = 0.128).
Univariate and multivariate analyses of the variables tested
for potential association with linezolid overexposure and under-
exposure are reported in tables 2 and 3, respectively. At multi-
variate logistic regression analysis, linezolid overexposure was
significantly associated with the presence of CrCLC-G estimates
≤40 mL/min. (OR 1.463; 95% CI 1.124–1.904, p = 0.005)
(table 2). Linezolid underexposure was significantly associated
with the presence of CrCLC-G estimates >100 mL/min. (OR
3.046; 95% CI 2.234–4.152, p < 0.001) (table 3). However,
linezolid Cmin did not correlate linearly with CrCLC-G
(R2 = 0.061) (fig. 3). Neither BMI nor TBW was associated
with the risk of linezolid under or overexposure.
Discussion
To our knowledge, this is the largest retrospective experience
ever reported of linezolid Cmin distribution during treatment
with conventional doses of 600 mg every 12 hr in a hospital-
wide population of adult patients.
Our group was among the first to show that linezolid expo-
sure may vary widely during conventional therapy with line-
zolid in adult patients [9]. We also provided some initial
understanding that maintenance of linezolid Cmin in the range
between 2 and 7 mg/L may optimize therapy and improve
safety outcome of long-term treatment with linezolid in adult
patients [10].
In the last years, other authors provided further evidence in
supporting the reliability of this range, either for therapeutic
Table 1.
Patients’ characteristics.
Total number of patients, n 1049
Total number of linezolid Cmin, n 2484
Age (years), median (IQR) 65 (52–74)
Gender, male/female, n (%) 717/332 (68.4/31.6)
Body-weight (kg), median (IQR) 74 (64–85)
BMI (kg/cm2), median (IQR) 25.0 (22.5–28.0)
Serum creatinine (mg/dL), median (IQR) 0.9 (0.7–1.2)
CrCLC-G (mL/min), median (IQR) 75.7 (35.3–124.3)
Linezolid route of administration,
oral/iv, n (%)
527/522 (50.2/49.8)
Linezolid Cmin (mg/L), median (IQR) 5.08 (2.78–8.52)
Linezolid Cmin distribution, n (%)
Desired therapeutic range (2–7 mg/L) 1262 (50.8)
Underexposure (<2 mg/L) 401 (16.2)
Overexposure (>7 mg/L) 821 (33.0%)
Mild (7.01–10 mg/L) 353 (14.2)
Moderate (10.01–20 mg/L) 370 (14.9)
Severe (>20 mg/L) 98 (3.9)
Ward of admission, n (%)
Medical ward 470 (44.8)
Surgical ward 369 (35.2)
ICU 210 (20.0)
BMI, body mass index; Cmin, plasma trough concentration; ICU,
intensive care unit; iv, intravenous route.
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efficacy or for safety purposes. Linezolid Cmins ≥ 2 mg/L
were associated with a probability higher than 80% of achiev-
ing bacterial eradication, and values > 6.3 mg/L were associ-
ated with a probability higher than 50% of developing
thrombocytopenia [16]. Likewise, it was shown in a toxicody-
namic model that linezolid concentration of 8.06 mg/L may
result in thrombocytopenia due to inhibition of the synthesis
of platelet precursor cells by 50% [8]. This is in agreement
with a recent study showing that mitochondrial toxicity risk
may increase with increasing linezolid Cmin [21]. Although
thrombocytopenia is the most notable example of dose-depen-
dent toxicity with linezolid, it should not be overlooked that
Fig. 1. Histogram and Kernel density plot of the distribution of linezolid trough concentrations. The rug plot along the x-axis illustrates the
marginal distribution of the concentrations.
Fig. 2. Beeswarm plot of the distributions of each linezolid trough concentrations in patients according to the type of ward of admission. The grey
shaded area identifies the desired therapeutic range (2–7 mg/L). Dashed line is the median. Dotted lines identify the 25th and the 75th percentile.
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also hyperlactacidaemia may be another dose-dependent toxic
effect occurring during linezolid treatment, which sometimes
may be life-threatening [11].
In the last year, several authors further supported the
hypothesis that TDM might represent the way forward for
optimizing linezolid therapy in specific subpopulations of
patients [17,18,20,22,23].
In this study, we had the opportunity of documenting the
distribution of linezolid Cmin during treatment at conventional
doses in more than one thousand adult patients admitted hospi-
tal-wide. Noteworthily, linezolid Cmin fell within the desired
range only in half of the cases. In the other half, we found that
the risk of drug overexposure was much higher than that of
drug underexposure. The distribution of linezolid Cmin among
the study population was not associated with TBW and/or with
BMI. This is in agreement with the findings of Bhalodi et al.
[24] showing that linezolid exposure in obese volunteers with
BMI of 30–54.9 kg/m2 receiving the fixed 600 mg every 12-hr
intravenous dose was similar overall to that of non-obese
patients, implying that dosage adjustments based on BMI alone
are not required. Likewise, distribution of linezolid Cmin in our
study population was not influenced by admission to medical
wards, surgical wards or the ICUs. This suggests that no speci-
fic condition related to the type of ward of admission (i.e. criti-
cal illness or surgery) may imply per se dosage adjustments. It
is worth mentioning that in our study, most of the TDM
instances came from the medical wards. This is in line with
the hospital-wide extension of our TDM linezolid programme
and may reflect the improved perceived usefulness of clinical
pharmacological advice for personalized drug dosing even out-
side of the ICUs, thanks to the educational interventions that
we carried out in recent years [20,25]. Among the tested vari-
ables, CrCLC-G was the only one that independently predicted
the risk of inappropriate linezolid exposure. CrCLC-G estimates
>100 mL/min. predicted the risk of drug underexposure,
whereas those <40 mL/min. predicted that of drug overexpo-
sure. This is in agreement with the findings of other authors
who showed that CrCL estimates >80 mL/min. were associ-
ated with the risk of linezolid Cmin < 2 mg/L [15], and those
<40 mL/min. were associated with that of Cmin > 8 mg/L [26].
Overall, these data suggest that TDM might be valuable for
linezolid especially in patients with severe renal impairment or
in those with augmented renal clearance. However, it should
not be overlooked that renal function seems to explain only
partially the very wide interindividual Cmin variability that we
observed in the study population. Noteworthily, no linear rela-
tionship between linezolid Cmin and CLCrC-G estimates was
observed. Additionally, it is worth mentioning that only 32%
of the patients with linezolid overexposure had also CLCrC-G
estimates ≤40 mL/min. This is in agreement with the finding
that renal clearance should account for around
30–40% of the total linezolid clearance [27].
Consistently, the wide interindividual variability of linezolid
Cmin should also be related to other causes. It has been
Table 2.
Univariate and multivariate analyses of variables tested for potential association with linezolid overexposure (Cmin > 7 mg/L).
Variables
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
TBW < 60 kg 1.162 (0.918–1.472) 0.213 – –
BMI ≤ 18 kg/m2 0.899 (0.608–1.331) 0.595 – –
CrCLC-G ≤ 40 mL/min 1.419 (1.095–1.838) 0.008 1.463 (1.124 – 1.904) 0.005
CrCLC-G, creatinine clearance estimated by means of the Cockcroft & Gault formula; BMI, body mass index; TBW, total body-weight. Bold values
relate to variables that resulted statistically significant at the multivariate analysis.
Table 3.
Univariate and multivariate analyses of the variables tested for potential association with linezolid underexposure (Cmin < 2 mg/L).
Variables
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
TBW > 100 kg 1.532 (1.040–2.256) 0.031 1.183 (0.676–2.073) 0.556
BMI > 25 kg/m2 0.948 (0.765–1.173) 0.621 – –
CrCLC-G ≥ 100 mL/min 3.091 (2.275–4.199) <0.001 3.046 (2.234–4.152) <0.001
CrCLC-G, creatinine clearance estimated by means of the Cockcroft & Gault formula; BMI, body mass index; TBW, total body-weight. Bold values
relate to variables that resulted statistically significant at the multivariate analysis.
Fig. 3. Relationship between linezolid trough levels (Cmin) and crea-
tinine clearance estimated by means of the Cockcroft and Gault for-
mula (CrCLC-G).
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postulated that linezolid may be a substrate of P-glycoprotein
[28]. P-gp inhibitors, such as omeprazole, amiodarone and
amlodipine, were associated with the risk of linezolid overexpo-
sure [9,14]. Conversely, P-gp inducers, such as rifampin,
levothyroxine and venlafaxine, were associated with that of
underexposure [10,12,13,29,30]. Unfortunately, in this study,
we did not have the chance to retrieve data on patients’ comedi-
cations. We had no opportunity to check all the clinical folders,
and the study data were retrieved from the patient TDM data
sheets stored at our institution. However, we believe that a sig-
nificant amount of the variability of linezolid Cmin might be
explained by drug–drug interactions. This is in line with the
huge 2-log degree of interindividual variability in linezolid Cmin
that was observed, suggesting that linezolid clearance could
have been nonlinear in the study population, as typically may
occur in the presence of inhibition or induction of the meta-
bolic/elimination pathways. This is in agreement with a recent
population pharmacokinetic study carried out among 20 ICU
patients showing that coadministration of P-gp inhibitors (i.e.
proton pump inhibitors) was associated with a trend to linezolid
overexposure, whereas that of P-gp inducers (i.e. levothyroxine)
caused exceedingly low drug exposure [18]. We are aware of
the importance of this, and we are planning a specific study in
order to address this issue in clinical practice.
Recently, other additional causes have been advocated. It
has been shown that the presence of acute respiratory distress
syndrome (ARDS), by increasing linezolid clearance, might be
a strong predictor of insufficient linezolid concentrations in
critically ill patients [19]. Prospective studies could clarify
whether other pathophysiological conditions could be involved
in affecting linezolid clearance.
While waiting for a better definition of the leading causes
of the linezolid variability, these data should further strengthen
the conviction that TDM might be a great opportunity for per-
sonalizing linezolid therapy in the majority of patients. This
could be especially valuable in preventing toxicity among
patients who are experiencing drug overexposure [11,31] and
in preventing therapeutic failure among patients who are expe-
riencing drug underexposure [19]. TDM might be of utmost
importance for preventing drug-related toxicity during long-
term treatment with linezolid, as, for example, for prosthetic
and/or bone and joint infections [4,32] and/or for MDR tuber-
culosis [5,7,21].
A recent retrospective study of a TDM programme carried
out among patients admitted to infectious disease units showed
that the adherence of clinicians to the TDM-guided dosage
adjustments recommended in the presence of linezolid overex-
posure was very low (<10%) [22]. This is in contrast to our
personal experience, and we agree with the authors’ claims
that this is a missed opportunity for clinicians. Since 2007, we
are providing clinicians with well-articulated and explanatory
clinical pharmacological advice for personalizing linezolid
therapy, and since then, the majority of feedback has been
positive. A recent 1-year retrospective audit of quality indica-
tors of clinical pharmacological advice for personalized line-
zolid dosing carried out at our university hospital confirmed
that in 2014, the clinicians’ adherence to TDM-guided dosage
adjustments of linezolid was very high (94.7%, 356/376) [20].
The very high clinician adherence rate to TDM-guided line-
zolid dosage adjustments has probably been favoured by the
educational and organizational interventions that we carried
out in recent years to improve the usefulness of clinical phar-
macological advice for personalized drug dosing based on
TDM [25].
We acknowledge that our study has several limitations. The
retrospective nature, the lack of data on clinical outcome on
the occurrence of adverse events and on comedications are
probably the most relevant. However, the study was focused
on dimensioning the interindividual variability of linezolid
exposure during conventional dosing regimens in routine clini-
cal practice, and the very large sample size of the study popu-
lation is a strength of this work.
In conclusion, our study provides evidence that linezolid
Cmin may vary widely in a large population of hospital-wide
adult patients. This variability is partially dependent on vari-
ability in renal function, but it is probably related also to other
factors such as drug–drug interactions and/or other pathophysi-
ological conditions. This suggests that TDM could represent
an opportunity to optimize therapy with linezolid in several
patients, especially when dealing with long-term treatment.
Prospective clinical studies are currently ongoing to provide
further evidence that this approach may be valuable in obtain-
ing therapeutic efficacy while preventing dose-dependent
drug-related adverse effects even in long-term treatments.
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